Skip to main content
TIANYU BIO-TECHNOLOGY CO.,LTD. logo

TIANYU BIO-TECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 603717 ISIN · CNE1000030W1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,621 across all filing types
Latest filing 2025-08-12 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603717

About TIANYU BIO-TECHNOLOGY CO.,LTD.

https://www.tianyubiotech.com/

TIANYU BIO-TECHNOLOGY CO.,LTD. specializes in the research, development, and large-scale production of active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates. The company focuses on therapeutic areas such as cardiovascular health, diabetes management, and anti-viral treatments. Its core product portfolio includes various sartan-based intermediates and other complex organic synthesis products. TIANYU BIO-TECHNOLOGY emphasizes rigorous quality management systems and adheres to international regulatory standards to ensure product safety and efficacy. By leveraging advanced chemical synthesis technologies and a robust R&D infrastructure, the company provides customized manufacturing solutions and high-quality chemical components to global pharmaceutical partners. Its operations are characterized by a commitment to technical innovation and process optimization in the synthesis of complex molecules.

Recent filings

Filing Released Lang Actions
关于归还募集资金及继续使用部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Tianyu Bio-Tech Co., Ltd. regarding the return and continued temporary use of idle raised funds to supplement working capital. It details the amounts involved, board and supervisory approvals, regulatory compliance, and the use of funds raised from a previous non-public stock issuance. The document is relatively short (3089 characters) and focuses on the announcement of the company's decision and compliance with regulations about the use of raised funds. It does not contain comprehensive financial statements or detailed financial performance data. Therefore, it is not an Annual Report, Interim Report, or Earnings Release. It is not a certification or a proxy statement. The content fits best with a Capital/Financing Update (CAP) as it relates to the management and use of capital raised through stock issuance and the temporary allocation of those funds. Hence, the classification is CAP with high confidence.
2025-08-12 Chinese
中德证券有限责任公司关于天域生物科技股份有限公司使用部分闲置募集资金暂时补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the use of idle raised funds by Tianyu Biotechnology Co., Ltd. It discusses the approval and use of funds raised through a non-public stock issuance, the return of previously used funds for temporary liquidity supplementation, and the continued use of idle raised funds for temporary liquidity needs. The document references regulatory rules and approvals, includes financial figures related to the raised funds, and contains opinions from the board, supervisory board, and the sponsoring institution. It is not a full annual or interim financial report, nor is it an earnings release or a simple announcement. It is a specialized audit or verification report related to the use of raised funds, which fits the category of an Audit Report / Information (AR). The document length is 2686 characters, which is short but contains substantive content and verification opinions, not just an announcement or certification. Therefore, the best classification is AR (Audit Report / Information). H1 2025
2025-08-12 Chinese
2025年7月养殖业务主要经营数据公告
Regulatory Filings Classification · 95% confidence The document is a monthly operating data announcement for July 2025 from Tianyu Bio-Technology Co., Ltd. It provides specific sales volume, revenue, and inventory data for the company's pig farming business. The document explicitly states that the data is unaudited and is provided as interim operational data for investor reference. It is not a full financial report, annual or quarterly, but rather a monthly business update. The document length is short (1173 characters), and it is clearly an announcement of operating data rather than a comprehensive financial report. Therefore, it fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like Interim Report (IR) or Earnings Release (ER).
2025-08-07 Chinese
关于控股股东所持公司部分股份质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the pledge of shares held by the controlling shareholders of the company. It details the number of shares pledged, the shareholders involved, the proportion of shares pledged relative to their holdings and the total company shares, and the impact of the pledge on the company. There is no financial statement, earnings data, or management discussion of financial results. The document is a regulatory announcement about share pledging by major shareholders, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or financial disclosure.
2025-08-05 Chinese
关于公司提起诉讼的公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement by Tianyu Bio-Tech Co., Ltd. regarding a lawsuit the company has initiated. It details the background of the investment, the performance commitment, arbitration results, and the current status of the legal proceedings. The document focuses on legal proceedings related to shareholder rights and financial compensation claims, with no actual financial statements or detailed financial data presented. It is a regulatory announcement about ongoing legal matters rather than a financial report or earnings release. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is 3763 characters, which is sufficient for a detailed legal update but not a full financial report. Hence, the classification is LTR with high confidence.
2025-07-29 Chinese
关于公司2025年度对外担保预计的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of the company's external guarantees for the year 2025. It details the guarantee amounts, the parties involved, internal decision procedures, and cumulative guarantee situations. It is a regulatory announcement about financial guarantees and risk exposure, not a full financial report or audit. The document is relatively short (2923 characters) and focuses on a specific financial update rather than comprehensive financial statements or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-22 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.